---
title: "Cerus Q4 revenue beats expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277518348.md"
datetime: "2026-03-02T21:08:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277518348.md)
  - [en](https://longbridge.com/en/news/277518348.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277518348.md)
---

# Cerus Q4 revenue beats expectations

)

Overview

-   Blood safety firm’s Q4 revenue beat analyst expectations
-   Company entered group purchasing agreement with Blood Centers of America during Q4

Outlook

-   Cerus expects 2026 product revenue between $224 mln and $228 mln
-   Company sees 2026 IFC revenue growing 20% to 30%
-   Cerus aims to improve global access to INTERCEPT technologies

Result Drivers

-   IFC DEMAND - Fourth quarter IFC demand increased over 50% year-over-year, contributing to revenue growth
-   EMEA PERFORMANCE - Strong EMEA performance in the platelets franchise and rollout of INT200 drove Q4 revenue growth Company press release:

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Beat $64.60 $58.08

Revenue mln mln (4

Analysts

)

### Q4 EPS -$0.01

Q4 Net $2.20

Income mln

Q4 Miss $3.40 $5.40

Adjusted mln mln (2

EBITDA Analysts

)

Q4 Gross 51.50%

Margin

Q4 Gross $29.70

Profit mln

### Q4 $37.20

Operatin mln

g

Expenses

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
-   The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy”
-   Wall Street’s median 12-month price target for Cerus Corp is $5.00, about 95.3% above its February 27 closing price of $2.56 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [CERS.US](https://longbridge.com/en/quote/CERS.US.md)

## Related News & Research

- [Cerus Director Timothy L. Moore to Step Down After Current Term](https://longbridge.com/en/news/273663896.md)
- [CERUS CORP CEO William Mariner Sells Shares](https://longbridge.com/en/news/279338077.md)
- [Cerus Corporation’s Q3 2025 Earnings: Growth Amid Challenges](https://longbridge.com/en/news/264942394.md)
- [Cerus Corporation: Strong Q3 Growth Overshadowed by Regulatory Delays and Uncertainty](https://longbridge.com/en/news/266191776.md)
- [Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors](https://longbridge.com/en/news/282730547.md)